Venetoclax (Bcl-2-selective inhibitor) is used to treat small lymphocytic lymphoma (SLL), which mainly promotes tumor cell apoptosis by inhibiting Bcl-2 and, ultimately, activating caspase-3 [24,25,26,27]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.